[Testing of cellular immune reactivity in melanoma patients with diphenylcyclopropenone in comparison to dinitrochlorobenzol].
Ten patients with malignant melanoma were simultaneously sensitized with dinitrochlorobenzol (DNCB) and diphenylcyclopropenon (DPCP) (500 micrograms each). Fourteen days after sensitization the patients were challenged with 0.04-25 micrograms doses of DNCB and DPCP. The reactions of all of the subjects tested were the same for DNCB as for DPCP. The results were statistically significant. To achieve a skin reaction of the same intensity, the necessary doses of DPCP were much lower than those of DNCB.
D003521:Cyclopropanes / Q000276:immunology*; D004137:Dinitrochlorobenzene / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance; D007111:Immunity, Cellular; D008545:Melanoma / Q000276:immunology*; D010328:Patch Tests; D012878:Skin Neoplasms / Q000276:immunology*
D003521:Cyclopropanes; D004137:Dinitrochlorobenzene; C029402:diphenylcyclopropenone
Testung der zellulären Immunreaktivität bei Melanompatienten mit Diphenylcyclopropenon (DPCP) im Vergleich mit Dinitrochlorobenzol (DNCB).